Related Experiment Video

Updated: Jul 13, 2026

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

FAF1 suppresses IkappaB kinase (IKK) activation by disrupting the IKK complex assembly

Min-Young Park1, Ji-hyun Moon, Ki-Sung Lee

  • 1Research Center for Biomedicinal Resources, PaiChai University, Daejeon 302-735, Korea.

The Journal of Biological Chemistry
|August 9, 2007
PubMed

Insights

Fas-associated factor 1 (FAF1) inhibits the activation of IkappaB kinase (IKK), a key step in NF-kappaB signaling. This molecular mechanism prevents excessive inflammation by blocking IKK complex formation.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Immunology

Background:

  • Nuclear factor-kappaB (NF-kappaB) is a crucial transcription factor regulating immune responses and inflammation.
  • Dysregulation of NF-kappaB signaling is implicated in various inflammatory diseases and cancer.
  • IkappaB kinase (IKK) activation is a central event in the NF-kappaB signaling pathway.

Purpose of the Study:

  • To elucidate the molecular mechanism by which Fas-associated factor 1 (FAF1) regulates IKK activation.
  • To investigate the interaction between FAF1 and IKK components.
  • To understand how FAF1 modulates NF-kappaB pathway activation.

Main Methods:

  • Co-immunoprecipitation assays to study protein interactions.
  • Western blotting to assess protein levels and activity.
  • Overexpression and depletion studies (siRNA) to evaluate FAF1's functional role.

Main Results:

  • FAF1 directly interacts with IKKbeta, particularly its leucine-zipper domain, upon stimulation with pro-inflammatory cytokines (TNF-alpha, IL-1beta) and LPS.
  • FAF1 binding disrupts IKK heterotrimer and homodimer formation and impairs IKKgamma recruitment.
  • Overexpression of FAF1 reduces IKKbeta activity, while FAF1 depletion enhances it, confirming its inhibitory role.

Conclusions:

  • FAF1 acts as a molecular inhibitor of IKK activation by interfering with IKK complex assembly.
  • This inhibition mechanism, coupled with cytoplasmic retention of NF-kappaB p65, provides a redundant suppression system for the NF-kappaB pathway.
  • FAF1 plays a critical role in preventing aberrant NF-kappaB activation, thereby maintaining immune homeostasis.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...